MORGAN STANLEY PLC/CALL/STRYKER CORP./440/0.1/20.06.25 Stock

Warrant

DE000MB7WKQ6

Real-time Bid/Ask 05:30:01 2024-05-20 EDT
0.6 EUR / 0.65 EUR +9.65% Intraday chart for MORGAN STANLEY PLC/CALL/STRYKER CORP./440/0.1/20.06.25
Current month-37.36%
1 month-45.71%
Date Price Change
24-05-17 0.57 -1.72%
24-05-16 0.58 -1.69%
24-05-15 0.59 +13.46%
24-05-14 0.52 -8.77%
24-05-13 0.57 -10.94%

Delayed Quote Börse Stuttgart

Last update May 17, 2024 at 02:09 pm

More quotes

Static data

Product typePlain-Vanilla-Warrants
Buy / SellCALL
Underlying STRYKER CORPORATION
Issuer Morgan Stanley
WKN MB7WKQ
ISINDE000MB7WKQ6
Date issued 2023-06-26
Strike 440 $
Maturity 2025-06-20 (397 Days)
Parity 10 : 1
Emission price 0.87
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 1.78
Lowest since issue 0.42
Spread 0.05
Spread %7.69%

Company Profile

Stryker Corporation is one of the world's leaders in designing, manufacturing, and selling orthopedic equipments. Net sales break down by family of products as follows: - surgical equipments and neurotechnology products (57.5%): electric motorized surgical instruments, surgical navigation systems, endoscopy equipment, digital imaging systems, neurosurgery equipments, neurovascular devices, etc. The group also offers hospital beds, gurneys, stretchers, and emergency room equipment; - orthopedic implants (42.5%): joint prostheses, traumatology implants, micro-implants, orthopedic cement, orthobiology products, etc. The group also provides spinal implants. At the end of 2022, the group had 48 production sites worldwide. Net sales are distributed geographically as follows: the United States (73.9%), Europe/Middle East/Africa (12.7%), Asia/Pacific (10.2%) and other (3.2%).
Sector
-
More about the company

Ratings for Stryker Corporation

Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings

Consensus: Stryker Corporation

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
29
Last Close Price
334.7 USD
Average target price
372.4 USD
Spread / Average Target
+11.26%
Consensus
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW